An ADC’s Path to Market Analysis of Difficulties and Key Points in ADC Process Scale up
An-ADCs-Path-to-Market-Analysis-of-Difficulties-and-Key-Points-in-ADC-Process-Scale-up.pdf – 552.59 KB
An-ADCs-Path-to-Market-Analysis-of-Difficulties-and-Key-Points-in-ADC-Process-Scale-up.pdf – 552.59 KB
An Antibody Drug Conjugate ( is a novel therapeutic agent which can deliver a highly potent traditional small molecule drug to a specific site or cell within the body It is formed when an active drug (the payload) is connected to an antibody using a linker The complex is referred to as an ADC
and it uses the cellular specificity of antibodies to direct the payload and deliver to the active disease site within the cell This enables ADCs to selectively treat cancer cells, tumor microenvironments, or other target cells, while reducing systemic, off target toxicity This targeted delivery of ADC agents has shown great promise and explosive growth in recent years.